News

Hydrogel punctal plugs may be a safe and viable method for delivery of anti-glaucoma drugs in the future.

The optimal time of implantation of a corneal inlay (Kamra, AcuFocus) to correct presbyopia in ametropic presbyopic patients seems to be 1 week after traditional LASIK in a planned two-stage KAMRA procedure.

Implantation of two stents (iStent, Glaukos) may be another option for controlling IOP in phakic and pseudophakic patients with open-angle glaucoma who are refractory to one anti-glaucoma medication.

Where leadership may once have been seen as crafting a master plan and handing down directives, today leadership manifests as a collaborative process.

Results of a randomized study show both superior and inferior visual field defects impair drivers’ performance on the computerized Hazard Perception Test. However, superior visual field loss is associated with significantly greater worsening than inferior visual field loss.

Selective laser trabeculoplasty provided a majority of Afro-Caribbean patients with a mean IOP reduction of 40% with no need for medical therapy.

An investigational glaucoma device that shunts aqueous from the anterior chamber to a sub-conjunctival/sub-Tenon’s pouch is being evaluated in a prospective study of 35 eyes operated on at two centers.

The outcomes for shunt implantation show promise as an option for the management of uveitic glaucoma. In a retrospective chart review, 73% of patients had a decrease of at least 20% in IOP 6 months postoperatively.

The electronic health records and electronic medical records implementations come with endless upgrades whether your clinic is prepared or not.

A corneal inlay improves near and intermediate vision with minimal compromise in distance acuity. Results are maintained over the long-term.

Nathan M. Radcliffe, MD, discusses use of laser technology for treating patients with early-stage glaucoma as an approach to decrease IOP or to reduce the need for IOP-lowering medications.

Several therapies are in the pipeline to treat Stargardt’s disease.

In this ongoing series of one-on-one interviews with key ophthalmic leaders, J.C. Noreika, MD, MBA, talks with Samuel Masket, MD, clinical professor of ophthalmology, David Geffen School of Medicine, Jules Stein Eye Institute, University of California, Los Angeles (UCLA). In his practice, Dr. Masket sees a high volume of patients referred for dysphototopsia and addresses issues related to the condition. Dr. Masket also highlights some of his many achievements and contributions to cataract and refractive surgery and tracks the field’s trends-from the infancy of phacoemulsification and lens implant cataract surgery to femtosecond lasers and extended depth-of-focus IOLs.

Observation of the episcleral venous fluid wave while performing canal-based glaucoma surgery provides intraoperative confirmation of accurate device placement, correlates with the extent of surgically induced canal cleavage, and may be a prognostic indicator for surgical success, said Ronald L. Fellman, MD.

The FDA has designated Dompé’s rhNGF (recombinant human nerve growth factor) as an orphan drug for the treatment of neurotrophic keratitis.

The FDA has issued 510(k) clearance to Nidek’s AL-Scan optical biometer.

Researchers from Massachusetts Eye and Ear, Harvard Medical School, and Boston University School of Medicine have found that the extent of retinal swelling due to cystoid macular edema (CME) was inversely related to dietary iodine intake in patients with retinitis pigmentosa (RP).

A new surgical advance-the Intrepid Balanced phacotips designed specifically for microcoaxial torsional ultrasound-has been found to have a significantly increased emulsification effect and markedly reduced shaft action compared with the traditional Kelman flared and mini-tips, said Khiun Tjia, MD.

Allergan has announced that, alongside its second-quarter financial results, it will reduce its workforce by about 1,500 employees-about 13% of its current global headcount-as part of efforts to boost stockholder value.

Bausch + Lomb has received 510(k) clearance from the FDA for its Victus femtosecond laser platform for laser-assisted lens fragmentation during cataract surgery.

AbbVie has reached a deal to buy Shire for $89.56 per share, or about $54.6 billion.

Genotyping reveals that certain patients with moderate age-related macular degeneration may benefit more from the AREDS formulation than others.

A nanophotonics-based device implanted in the eye may one day enable patients with glaucoma to monitor their IOP from home.

As technology continues to advance, the ability to serve patients will greatly improve. Having sophisticated tools at our disposal will make medical decisions all the more appropriate and treatment plans all the more effective.

Using a new analytic approach to dig deeper into data from genome-wide association studies, researchers have found several common mechanisms underlying IOP.

Much work is being done with Adeno-associated virus (AAV) vectors for application in retinal gene therapy, with modifications being made to the capsid and genome of the vector to generate novel variants with unique transduction profiles, according to Shannon Boye, PhD.

The FDA has granted 510(k) clearance to Quantel Medical’s integrated laser platform, Optimis Fusion.

Zeiss has unveiled a new product-Zeiss Digital Lens-that targets the vision needs of the millennial generation. The company will also launch a consumer marketing approach designed to raise awareness and drive demand for the product.